opnMe News

Let´s live innovation. Want to know the latest news and trends? Read more

Subscribe to our newsletter to stay up to date with latest developments

Latest news

18 February 2019

Now, scientists from all over world can access our molecule completely free of charge without any shipment costs to pursue further pre-clinical research independently of us.

11 February 2019

The opnMe team is pleased to announce the addition of BI 224436 to its molecules 2 order program. Now, scientists from all over the world can access our molecule completely free of charge without any shipment costs.

21 January 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is now seeking novel applications of its lung-specific gene therapy vector AAV2-L1 in pulmonary diseases.

09 January 2019

Boehringer Ingelheim is to make the BET degrader compound MZ 1 available through its opnMe.com portal. The company actively supports open access in order to boost progress in biomedical and drug discovery research. MZ 1 (created at the University of Dundee) is the first external compound to be added to Boehringer Ingelheim’s’ opnMe.com portal.

read more...

Prof. Dr. Alessio Ciulli, University of Dundee. One of the pioneers in the field of PROTACs

07 January 2019

The University of Dundee announced today that a PROTAC compound developed at its institution is being made available free of charge by us through our scientific crowdsourcing platform opnMe.com.

11 December 2018

Earlier this year, we had asked you whether we should launch GSK-3 or Chymase inhibitor as the next molecule to opnMe.com? Eventually, the majority voted for GSK-3. However, subsequently several researchers have contacted us to inquire whether we would be willing to release our Chymase inhibitor as well?

19 Sept 2018

"A small step for us, but a big step to the research community"

We are happy to announce that we have added the first small molecule STEP (PTPN5) activator, BI-0314, that binds to the phosphatase domain and upregulates the catalytic activity of STEP to our opnMe.com portal.

04 June 2018

New ideas for molecules? He initiated the opnMe.com crowdsourcing platform - and received great reception. In a short period of time, hundreds of molecule orders and many new ideas for scientific research collaboration projects were received. #ResearchOnStage @BoehringerDE

read more...

04 June 2018

As of today, Boehringer Ingelheim offers you another well-characterized and potent inhibitor via opnMe.com: BI-4659 inhibits Alk5 which is also known as TGFβR1. Therapeutic approaches to inhibit TGFβ receptor I (TGFβRI/Alk5) signaling have been discussed for the treatment of several diseases such as idiopathic pulmonary fibrosis and cancer.

17 May 2018

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is now seeking novel disease hypotheses for its Complex I ROS modulators.